Leonard Zehr, Author at BioTuesdays

Feature

Beyond Air’s cylinder-free nitric oxide delivery system for respiratory conditions

Beyond Air (NASDAQ:XAIR), formerly AIT Therapeutics, is developing a proprietary nitric oxide (NO) generator and delivery system that uses NO generated from ambient air, rather than bulky cylinders, and delivers precise...

August 20, 2019

Feature

PharmAust readies pivotal trial in Australia to treat cancer in dogs

PharmAust (ASX:PAA) is gearing up to begin a pivotal Phase 2 study in Australia with its lead veterinary drug candidate, monepantel, for the treatment of lymphoma in canines, which if successful, could open the door to...

August 12, 2019

Feature

Theralase Phase 2 NMIBC clinical study could support marketing application

Theralase Technologies (TSXV:TLT; OTCQB:TLTFF) has designed its Phase 2 clinical study in patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) based on FDA industry guidance issued in February 2018.

August 6, 2019

Feature

PharmaCyte’s Cell-in-a-Box encapsulation technology targeting cancer, diabetes

PharmaCyte Biotech (OTCQB:PMCB) is developing cellular therapies for its lead pancreatic cancer program and for diabetes that are based on a proprietary cellulose-based live cell encapsulation technology known as a Cell...

July 23, 2019

Feature

Stifel analyst discusses emerging NASH therapeutic space

As a director and senior analyst covering the biotechnology sector at Stifel, Derek Archila combines analytic ability and industry experience. He has held executive positions covering biotechnology and specialty...

July 12, 2019

Feature

Helius Medical rolling out PoNS treatment for mmTBI in Canada

Helius Medical Technologies (NASDAQ:HSDT; TSX:HSM) is transitioning from a development- to commercial-stage company as it rolls out its Health Canada-cleared PoNS medical device for the treatment of chronic balance...

July 2, 2019

Feature

Zenabis sets sights on becoming leading cannabis producer

By Len Zehr Despite being a new entrant in the cannabis market, Zenabis Global (TSX:ZENA) is making huge strides to become one of the largest licensed producers of medical and adult-use recreational cannabis in Canada...

June 11, 2019

Feature

BriaCell advancing potential breakthrough immunotherapy for advanced breast cancer

By Len Zehr BriaCell Therapeutics (TSXV:BCT; OTCQB:BCTXF) has reported impressive early safety and efficacy data with its lead immunotherapies for the treatment of advanced breast cancer. “Right now, there is no...

May 21, 2019

Feature

MediXall transforming patient-healthcare provider experience

By Len Zehr MediXall Group (OTCQB:MDXL) has launched a new generation healthcare marketplace platform to address self-pay and high deductible consumers’ growing need for greater healthcare cost transparency and access...

May 14, 2019

Feature

Ceapro transitioning to biopharmaceutical company from contract manufacturer

By Len Zehr Ceapro (TSXV:CZO) is transitioning to a new business model – from a contract manufacturer to a biopharmaceutical company – to pursue multiple growth opportunities in nutraceuticals and...

May 7, 2019

Author - Leonard Zehr

Beyond Air’s cylinder-free nitric oxide delivery system for respiratory conditions

PharmAust readies pivotal trial in Australia to treat cancer in dogs

Theralase Phase 2 NMIBC clinical study could support marketing application

PharmaCyte’s Cell-in-a-Box encapsulation technology targeting cancer, diabetes

Stifel analyst discusses emerging NASH therapeutic space

Helius Medical rolling out PoNS treatment for mmTBI in Canada

Zenabis sets sights on becoming leading cannabis producer

BriaCell advancing potential breakthrough immunotherapy for advanced breast cancer

MediXall transforming patient-healthcare provider experience

Ceapro transitioning to biopharmaceutical company from contract manufacturer

Subscribe